April 06, 2026
(Monday)
Introduction: The Quiet Power of Small-Cap Conviction
While the Indian stock market reels under geopolitical pressure today — with the SENSEX trading around 72,822 (down ~500 points) and NIFTY 50 at approximately 22,572 (down ~141 points) amid Iran tensions and FII selling — there is one investor whose approach to market volatility has consistently turned chaos into compounding wealth.
Her name is Dolly Khanna — a Chennai-based investor often called the “Queen of Small Caps” — and her portfolio, managed by her husband Rajiv Khanna, has delivered some of the most spectacular multibagger returns in Indian stock market history. With a current net worth of approximately ₹226.6 crore (as of January 2026), the Khanna portfolio is a masterclass in finding hidden gems before the crowd discovers them.
Today, I want to decode her entire investment framework — the exact criteria she uses, the sectors she targets, her contrarian timing, and her disciplined exit strategy — so that YOU can apply these same principles to identify multibagger small-cap stocks in the Indian market.
Who Is Dolly Khanna? The Story Behind the Legend
Dolly Khanna is not your typical Dalal Street personality. She doesn’t give interviews on CNBC-TV18. She doesn’t tweet stock tips. She doesn’t run a PMS or AIF. She is a private investor from Chennai whose quarterly shareholding disclosures (mandatory under SEBI regulations when holding more than 1% in a company) are tracked by millions of retail investors across India.
The portfolio is held in Dolly Khanna’s name, but the investment decisions are made by her husband, Rajiv Khanna, a graduate of IIT Madras. Rajiv is a fundamentals-driven investor who has spent decades refining a bottom-up stock-picking framework that focuses exclusively on small-cap and mid-cap companies in traditional Indian industries.
What makes the Khanna approach remarkable is its simplicity and discipline. They don’t use complex algorithms. They don’t trade derivatives. They don’t chase momentum. Instead, they methodically identify businesses with strong fundamentals trading at reasonable valuations — and then they hold with conviction until the thesis plays out or breaks down.
The Dolly Khanna Investment Framework: 6 Non-Negotiable Criteria
Based on publicly available information about the Khanna portfolio’s patterns, here are the six key criteria that define their stock selection process:
Criterion 1: Sales Growth of at Least 15%
The Khannas look for companies demonstrating consistent top-line growth of at least 15% annually. This is not about one exceptional quarter — it’s about a sustained revenue trajectory that signals genuine demand for the company’s products or services. A company growing revenue at 15%+ is typically gaining market share, expanding capacity, or benefiting from structural demand tailwinds in its sector.
Why 15%? Because in the Indian context, nominal GDP growth hovers around 10-12%. A company growing sales at 15%+ is outpacing the economy — a sign of competitive strength.
Criterion 2: Profit Growth of at Least 20%
Revenue growth is meaningless if it doesn’t translate into profit growth. The Khannas require profit growth of at least 20% — which means the company’s margins are either stable or expanding as it scales. When profit growth exceeds revenue growth, it signals operating leverage — the hallmark of a well-managed, scalable business.
Consider Titan Biotech (BSE: 524717), currently trading at ₹529 with a market cap of ₹2,187 crore. Titan Biotech’s operating profit margins have expanded from approximately 10% to over 17-19% over recent years — exactly the kind of operating leverage that the Khanna framework would flag as a positive signal. With an ROCE of 16.9% and ROE of 15%, Titan Biotech exemplifies the type of quality small-cap compounder that fits this criterion.
Criterion 3: ROCE of at Least 15%
Return on Capital Employed (ROCE) is the Khannas’ quality filter. They require an ROCE of at least 15%, which ensures the business is generating adequate returns on the capital invested in it. A high ROCE means the company doesn’t need to burn excessive capital to grow — it can fund growth from internal accruals.
Titan Biotech’s ROCE of 16.9% clears this threshold comfortably. The reason ROCE matters so much in small-cap investing is that many small companies can show high revenue growth simply by throwing capital at the problem (building factories, increasing inventory, extending credit). But if that growth comes with an ROCE below 10%, the company is actually destroying value even as its top line grows.
Criterion 4: Promoter Holding of 50% or More
The Khannas strongly prefer companies where the promoter holds at least 50% stake. This criterion serves multiple purposes: it ensures the promoter has significant “skin in the game,” it reduces the risk of hostile takeovers or management instability, and it signals that the promoter is confident enough in the business to maintain a controlling stake rather than diluting or selling down.
In Indian small caps, promoter holding is especially important because corporate governance standards can be uneven. A promoter with 50%+ ownership is essentially betting their own family wealth on the company’s success — which powerfully aligns their interests with minority shareholders like you and me.
Criterion 5: Interest Coverage Ratio Above 4x
Financial strength is non-negotiable. The Khannas require an interest coverage ratio of at least 4x, meaning the company’s operating profit covers its interest payments at least four times over. This ensures the company has a comfortable debt service buffer and is not at risk of financial distress even during economic downturns.
This is especially relevant today, when interest rates remain elevated and many overleveraged companies are struggling. A strong interest coverage ratio provides the financial cushion that allows a small-cap company to survive tough periods and emerge stronger — exactly what you need for a multi-year holding period.
Criterion 6: Price-to-Sales Ratio Below 1x
This is perhaps the most distinctive and powerful criterion in the Khanna framework. They target companies trading at a Price-to-Sales (P/S) ratio below 1x — meaning the market is valuing the entire company at less than its annual revenue.
Why is this so powerful? Because a P/S below 1x typically means the market is either ignoring the company (lack of analyst coverage, no institutional interest) or is pricing in temporary headwinds that will likely reverse. For a company that also meets the 15% sales growth and 15% ROCE criteria, a P/S below 1x represents a significant valuation mismatch — the classic setup for a multibagger.
The Dolly Khanna Sector Playbook: Where She Hunts
The Khanna portfolio is heavily concentrated in traditional, old-economy sectors that most glamour-chasing investors completely ignore. This is deliberate — and it’s one of their biggest edges.
Their preferred hunting grounds include:
Manufacturing: Companies making physical products — from steel to paper to industrial goods. These businesses have tangible assets, predictable demand, and often benefit from India’s infrastructure and industrial growth story.
Textiles: India’s textile sector is a massive export opportunity, and many small-cap textile companies trade at absurdly low valuations relative to their revenue and export potential. The Khannas have made significant returns from textile stocks.
Chemicals: India is emerging as a global alternative to China in specialty chemicals manufacturing. Small-cap chemical companies with strong R&D and customer relationships often fit all six Khanna criteria perfectly.
Sugar: The sugar sector in India is cyclical, but the Khannas have shown remarkable ability to time their entries near the bottom of the sugar cycle and ride the recovery to multibagger returns.
Notably, the Khannas avoid banking, technology, and government-owned firms. Their reasoning is sound — banking requires specialized analysis of asset quality, technology companies often trade at rich valuations, and PSU stocks carry governance and policy risks that are hard to quantify.
The Contrarian Timing Edge: Buy Before the Crowd Notices
One of Dolly Khanna’s biggest competitive advantages is her timing. The Khannas consistently enter stocks before they appear on anyone’s radar. By the time financial media starts covering a stock and institutional investors begin taking positions, the Khannas have often been holding it for quarters — having bought in at rock-bottom valuations.
This is the exact opposite of what most retail investors do. Most investors buy after a stock has already rallied 200-300% and is being featured in “top multibagger” lists. By then, most of the easy returns have already been captured. The Khannas buy when the stock is boring, undiscovered, and cheap — which is when the risk-reward ratio is most favorable.
On a day like today, when markets are falling sharply and fear is dominating, the Khanna mindset would be to look for quality small-caps that are being indiscriminately sold by panicking investors. As Warren Buffett famously said: “Be fearful when others are greedy, and greedy when others are fearful.”
The Disciplined Exit Strategy: The 30-Day Moving Average Rule
While much attention is paid to what the Khannas buy, their exit strategy is equally important. Reports suggest they closely monitor the 30-day moving average of their holdings. When a stock consistently trades below its 30-day moving average or starts underperforming their expectations, they systematically reduce their position.
This is a brilliant hybrid approach — combining fundamental analysis for entry with technical discipline for exit. Too many fundamental investors fall in love with their stocks and refuse to sell even when the thesis has clearly broken down. The Khannas avoid this trap by using an objective, rule-based exit mechanism.
Their recent portfolio moves illustrate this discipline. In the December 2025 quarter, they reduced their stake in Prakash Industries (one of their oldest holdings at ₹51.5 crore) by 0.4% to 2.6%. They also trimmed Som Distilleries from 2.4% to 2.1% in the September 2025 quarter. These aren’t panic sales — they’re methodical position adjustments based on their framework.
Legendary Multibaggers from the Khanna Portfolio
The proof of any investment strategy is in its results. The Khanna portfolio has produced several legendary multibaggers over the years:
Rain Industries: The Khannas identified this carbon products manufacturer early, and the stock delivered extraordinary returns as the company benefited from global commodity cycles and growing demand for its specialty products.
Avanti Feeds: This shrimp feed and processing company was a classic Khanna pick — a small-cap in a niche industry with strong fundamentals, high promoter holding, and low valuations. The stock delivered multibagger returns before the Khannas eventually trimmed their position.
NOCIL: India’s leading rubber chemicals manufacturer, NOCIL was another under-the-radar pick that fit the Khanna criteria perfectly — niche market leadership, strong margins, and low institutional coverage.
Polyplex Corporation: A polyester films manufacturer that the Khannas identified early in its growth cycle, before institutional investors took notice.
How to Apply the Dolly Khanna Framework in Today’s Market
Here’s a practical step-by-step approach to implement the Khanna framework in your own investing:
Step 1: Screen for quantitative criteria. Use free screeners like Screener.in to filter for companies with sales growth >15%, profit growth >20%, ROCE >15%, promoter holding >50%, interest coverage >4x, and P/S ratio <1x. This will immediately narrow the universe from 5,000+ listed companies to perhaps 30-50 candidates.
Step 2: Focus on traditional sectors. Prioritize manufacturing, textiles, chemicals, sugar, and other old-economy sectors. Skip banking, IT, and PSUs. Look for companies in sectors benefiting from structural tailwinds like China+1, PLI schemes, or rising domestic consumption.
Step 3: Deep-dive into the shortlist. For each candidate, read at least 3 years of annual reports. Understand the business model, competitive position, capital allocation track record, and management quality. Use our 95-factor analysis framework to evaluate each company comprehensively.
Step 4: Concentrate your capital. As Warren Buffett wisely said: “Wide diversification is only required when investors do not understand what they are doing.” The Khannas themselves typically hold only about 10 active positions at any given time. If you’ve done deep research and have genuine conviction, concentrate your capital in your best 5-10 ideas rather than diluting returns across 50 mediocre picks.
Step 5: Set exit rules before you buy. Decide in advance what conditions would cause you to sell — whether it’s a fundamental deterioration, a technical breakdown below the moving average, or a change in the original investment thesis. Having pre-set exit rules eliminates emotional decision-making.
Why F&O Gambling Will Never Match This Approach
According to SEBI’s own study, 9 out of 10 individual traders in the equity Futures & Options segment incurred net losses. F&O trading is essentially gambling — the house (brokers, exchanges, and professional traders) always wins in the long run.
Compare that with the Dolly Khanna approach: patient identification of fundamentally strong small-caps, buying at reasonable valuations, holding with conviction, and exiting with discipline. This is not gambling — this is intelligent capital allocation. It’s how real wealth is built in the Indian stock market.
If you want to learn systematic value investing rather than gambling in F&O, check out our complete free course: Value Investing Course by Manish Goel.
The Titan Biotech Connection
While Titan Biotech (BSE: 524717) is not a Dolly Khanna holding, it shares many characteristics with the type of stocks she targets: a niche market leader in biotechnology and life sciences products, strong operating margins, impressive ROCE of 16.9%, ROE of 15%, a virtually debt-free balance sheet, and a business that’s under the radar of most institutional investors.
At the current price of ₹529 with a market cap of ₹2,187 crore, Titan Biotech represents the kind of quality small-cap compounder that fits the philosophy of finding great businesses before the crowd arrives — exactly what the Dolly Khanna framework teaches us to look for.
Key Takeaways
The Dolly Khanna investment framework isn’t rocket science — it’s disciplined, patient, fundamental analysis applied to the most overlooked corner of the Indian stock market. The six criteria (15% sales growth, 20% profit growth, 15% ROCE, 50%+ promoter holding, 4x interest coverage, P/S below 1x) create a powerful filter that eliminates most stocks and highlights only the highest-quality candidates.
Remember: the greatest wealth in Indian stock markets has always been created by investors who bought quality small-caps early, held with conviction, and let compounding do the heavy lifting. Dolly Khanna’s track record is living proof that this approach works — and you can replicate it with discipline, patience, and deep research.
Stay focused on quality. Stay concentrated. Stay patient. That’s how multibaggers are born.
📢 Join Our Telegram Channel
Get daily value investing lessons, stock analysis & Titan Biotech updates — delivered straight to your phone!
✈️ Join @longtermequityy on Telegram
🔔 Free • No spam • Value investing insights daily
Disclaimer: This article is for educational and informational purposes only. It is not investment advice, and not a buy, sell, or hold recommendation on any stock mentioned, including Titan Biotech Limited. Equity markets carry risk; please do your own research or consult a qualified professional before making investment decisions.
